Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28:2947–2951.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–2909.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Targeted cancer therapies. [cited 2016 Aug 01]. Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
   Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–3140.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–3318.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Liang B, Wang S, Zhu XG, et al. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. WJG. 2005;11:623–628.
   PubMed Web of Science ®Google Scholar
• Iwase T, Tanaka M, Suzuki M, et al. Identification of protein-tyrosine kinase genes preferentially expressed in embryo stomach and gastric cancer. Biochem Biophys Res Commun. 1993;194:698–705.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Garcia-Carbonero R, Cassidy J, et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res. 2013;19:2541–2550.
   PubMed Web of Science ®Google Scholar
• Wu J. Statistical inference for tumor growth inhibition T/C ratio. J Biopharm Stat. 2010;20:954–964.
   PubMed Web of Science ®Google Scholar
• Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol. 2002;20:1775–1785.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim YS, Bang S, et al. ATP-based chemotherapy response assay in patients with unresectable gastric cancer. Oncology. 2007;73:439–440.
   PubMed Web of Science ®Google Scholar
• Han ME, Jeon TY, Hwang SH, et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci. 2011;68:3589–3605.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Timm M, Haug JL, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010;29:1190–1202.
   PubMed Web of Science ®Google Scholar
• Mangana J, Levesque MP, Karpova MB, et al. Sorafenib in melanoma. Expert Opin Investig Drugs. 2012;21:557–568.
   PubMed Web of Science ®Google Scholar
• Tesei A, Leonetti C, Zupi G, et al. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med. 2011;15:316–326.
   PubMed Web of Science ®Google Scholar
• Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Meth Enzymol. 2006;407:597–612.
   PubMed Web of Science ®Google Scholar
• Panka DJ, Wang W, Atkins MB, et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611–1619.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–239.
   PubMed Web of Science ®Google Scholar
• Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 2008;13:845–858.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou X, Shen H, et al. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41.
   PubMed Web of Science ®Google Scholar
• Yoon H, Min JK, Lee JW, et al. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun. 2011;405:333–337.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249–279.
   PubMedGoogle Scholar
• Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012;30:306–315.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kiyota N, Fuse N, et al. A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric Cancer. 2014;17:161–172.
   PubMed Web of Science ®Google Scholar
• Rausch V, Liu L, Kallifatidis G, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010;70:5004–5013.
   PubMed Web of Science ®Google Scholar
• Sunayama J, Matsuda K, Sato A, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells. 2010;28:1930–1939.
   PubMed Web of Science ®Google Scholar
• Yang S, Ngo VC, Lew GB, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther. 2009;8:2537–2545.
   PubMed Web of Science ®Google Scholar